BLRX - BioLineRx rallies on positive late-stage data on lead candidate

Thinly traded nano cap BioLineRx (BLRX) jumps 45% premarket on robust volume in reaction to positive preliminary results from a Phase 3 clinical trial, GENESIS, evaluating lead candidate motixafortide for stem cell mobilization in multiple myeloma patients.Based on a preplanned interim analysis of the primary endpoint, the independent Data Monitoring Committee recommended that the study be stopped early due to the strength of the results.Complete results, including secondary and exploratory efficacy endpoints, as well as extended safety data, will be announced after the last patient enrolled reaches 100 days of follow-up post-transplantation, expected to occur in H1 2021.

For further details see:

BioLineRx rallies on positive late-stage data on lead candidate